Shariaportfolio Inc. Has $2.19 Million Position in Johnson & Johnson (NYSE:JNJ)

Shariaportfolio Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,115 shares of the company’s stock after selling 304 shares during the period. Johnson & Johnson comprises approximately 1.0% of Shariaportfolio Inc.’s portfolio, making the stock its 12th largest position. Shariaportfolio Inc.’s holdings in Johnson & Johnson were worth $2,186,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. IFS Advisors LLC lifted its stake in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $31,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $35,000. Finally, Activest Wealth Management acquired a new position in Johnson & Johnson in the third quarter valued at $40,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Stifel Nicolaus lowered their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Guggenheim lifted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Leerink Partners dropped their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 2.0 %

JNJ opened at $162.75 on Thursday. The firm has a market capitalization of $391.83 billion, a PE ratio of 24.47, a P/E/G ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company’s 50-day moving average is $150.08 and its 200 day moving average is $155.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the company earned $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.05%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.